SG11201900500TA - Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof - Google Patents
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereofInfo
- Publication number
- SG11201900500TA SG11201900500TA SG11201900500TA SG11201900500TA SG11201900500TA SG 11201900500T A SG11201900500T A SG 11201900500TA SG 11201900500T A SG11201900500T A SG 11201900500TA SG 11201900500T A SG11201900500T A SG 11201900500TA SG 11201900500T A SG11201900500T A SG 11201900500TA
- Authority
- SG
- Singapore
- Prior art keywords
- gitr
- international
- ligand
- glucocorticoid
- necrosis factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 January 2018 (25.01.2018) WIP0 I PCT omit °nolo omm 111E1111°111 (10) International Publication Number WO 2018/018039 A3 (51) International Patent Classification: (07x16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/043504 (22) International Filing Date: 24 July 2017 (24.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/365,712 22 July 2016 (22.07.2016) US 62/375,634 16 August 2016 (16.08.2016) US (71) Applicant: DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue, Boston, Massachu- setts 02215 (US). (72) Inventors: MARASCO, Wayne A.; 43 Rice Street, Wellesley, Massachusetts 02481 (US). ZHU, Quan Karen; 9 Carraige Hill Circle, Southborough, Massachusetts 01772 (US). (74) Agent: ELRIFI, Ivor et al.; Cooley LLP, 1299 Pennsylva- nia Avenue, Suite 700, Washington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 22 February 2018 (22.02.2018) = (54) Title: GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF Figure 12 GITR-Ligand vs E1-3H7 IgG4 GITR-Ligand vs TT1-3C6 IgG4 GITR-ligand vs GT1-10 IgGI cc 0 2000 4000 6000 0 2000 4000 6000 0 2000 4000 6 0 00 ngfml ngtml ngiml Anti-GITR-mAb Anti-GITR ImAb &GITRL GITR-Ligand at 333nem1 (57) : The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer. Cr) Cr) O GC 11 O 00 11 O C 4.00E+03 2,00E-F03 0.00E+00 2.00E+04 1.80E+04 1,60E+04 1.40E+04 1.20E-F04 1.00E-F04 8.00E+03 6.00E+03 r 61 \ — — A .... . * .......... prh - A ----------------------------------------------
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662365712P | 2016-07-22 | 2016-07-22 | |
US201662375634P | 2016-08-16 | 2016-08-16 | |
PCT/US2017/043504 WO2018018039A2 (en) | 2016-07-22 | 2017-07-24 | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900500TA true SG11201900500TA (en) | 2019-02-27 |
Family
ID=59501631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900500TA SG11201900500TA (en) | 2016-07-22 | 2017-07-24 | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
Country Status (13)
Country | Link |
---|---|
US (2) | US11046777B2 (en) |
EP (1) | EP3487884A2 (en) |
JP (1) | JP7082967B2 (en) |
KR (1) | KR102534568B1 (en) |
CN (2) | CN116082506A (en) |
AU (2) | AU2017300788B2 (en) |
BR (1) | BR112019001262A2 (en) |
CA (1) | CA3031194A1 (en) |
IL (2) | IL296127A (en) |
MX (1) | MX2019000963A (en) |
RU (1) | RU2019104896A (en) |
SG (1) | SG11201900500TA (en) |
WO (1) | WO2018018039A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210070860A1 (en) * | 2018-03-21 | 2021-03-11 | Dana-Farber Cancer Institute, Inc. | Fc variant compositions and methods of use thereof |
KR20200140882A (en) * | 2018-04-09 | 2020-12-16 | 오리진셀 테라퓨틱스 코포레이션, 엘티디. | Anti-PD-L1 antibody and uses thereof |
AU2021356355A1 (en) * | 2020-10-09 | 2023-05-25 | The Hospital For Sick Children | Polypeptides targeting sars-cov-2 and related compositions and methods |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
DE3788058T2 (en) | 1986-08-28 | 1994-04-21 | Teijin Ltd | CELL TOXIC ANTIBODY COMPLEX AND METHOD FOR THE PRODUCTION THEREOF. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
KR100252547B1 (en) | 1991-09-05 | 2000-09-01 | 프레드 마리얀스키 | Targeted delivery of poly- or oligonucleotides to cells |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
DK0669836T3 (en) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Therapeutic use of chimeric and radiolabeled antibodies and human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
EP2502935B1 (en) | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US20090130123A1 (en) * | 2004-06-15 | 2009-05-21 | Erol Fikrig | Antibodies to west nile virus polypeptides |
DK2343320T3 (en) | 2005-03-25 | 2018-01-29 | Gitr Inc | ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF |
PL3023438T3 (en) * | 2009-09-03 | 2020-07-27 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
AR097306A1 (en) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | MODULATION OF TUMOR IMMUNITY |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
NZ726513A (en) * | 2014-05-28 | 2023-07-28 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
LT3151921T (en) | 2014-06-06 | 2019-12-10 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
RU2017115315A (en) * | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | ANTIBODIES TO A GLUCCORTICOID-INDUCED TUMOR NECROSIS FACTOR (GITR) RECEPTOR AND METHODS OF APPLICATION |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
WO2016073906A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
-
2017
- 2017-07-24 BR BR112019001262-1A patent/BR112019001262A2/en unknown
- 2017-07-24 WO PCT/US2017/043504 patent/WO2018018039A2/en unknown
- 2017-07-24 AU AU2017300788A patent/AU2017300788B2/en active Active
- 2017-07-24 KR KR1020197005244A patent/KR102534568B1/en active IP Right Grant
- 2017-07-24 IL IL296127A patent/IL296127A/en unknown
- 2017-07-24 US US16/319,590 patent/US11046777B2/en active Active
- 2017-07-24 EP EP17746345.2A patent/EP3487884A2/en active Pending
- 2017-07-24 CN CN202211582061.4A patent/CN116082506A/en active Pending
- 2017-07-24 CN CN201780054915.2A patent/CN109689689B/en active Active
- 2017-07-24 SG SG11201900500TA patent/SG11201900500TA/en unknown
- 2017-07-24 RU RU2019104896A patent/RU2019104896A/en unknown
- 2017-07-24 MX MX2019000963A patent/MX2019000963A/en unknown
- 2017-07-24 JP JP2019503341A patent/JP7082967B2/en active Active
- 2017-07-24 CA CA3031194A patent/CA3031194A1/en active Pending
-
2019
- 2019-01-21 IL IL264376A patent/IL264376A/en unknown
-
2021
- 2021-05-10 US US17/316,141 patent/US20220098314A1/en active Pending
-
2024
- 2024-02-15 AU AU2024200994A patent/AU2024200994A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019001262A2 (en) | 2019-05-07 |
CN109689689A (en) | 2019-04-26 |
CN116082506A (en) | 2023-05-09 |
JP7082967B2 (en) | 2022-06-09 |
RU2019104896A3 (en) | 2021-04-29 |
US20210101989A1 (en) | 2021-04-08 |
MX2019000963A (en) | 2019-11-28 |
KR102534568B1 (en) | 2023-05-18 |
IL296127A (en) | 2022-11-01 |
JP2019524111A (en) | 2019-09-05 |
AU2017300788B2 (en) | 2023-11-16 |
WO2018018039A3 (en) | 2018-02-22 |
WO2018018039A2 (en) | 2018-01-25 |
RU2019104896A (en) | 2020-08-24 |
EP3487884A2 (en) | 2019-05-29 |
IL264376A (en) | 2019-02-28 |
KR20190039532A (en) | 2019-04-12 |
CA3031194A1 (en) | 2018-01-25 |
CN109689689B (en) | 2022-12-06 |
US20220098314A1 (en) | 2022-03-31 |
NZ750097A (en) | 2023-11-24 |
AU2017300788A1 (en) | 2019-02-07 |
AU2024200994A1 (en) | 2024-03-07 |
US11046777B2 (en) | 2021-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201810883TA (en) | Combination therapy | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201805420SA (en) | Antibodies and conjugates thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) |